HUMAN CANCER BIOLOGY

1353
Murine Microenvironment Metapathways Associate with Human Cancer Etiology and Intrinsic Subtypes
David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, and Mary Helen Barcellos-Hoff

1363
PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshiooka, Norio Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma, Kenzo Kosaka, and Ikuo Konishi

1375
Rab25 Regulates Invasion and Metastasis in Head and Neck Cancer
Panomwat Amornphimoltham, Kamal Rechache, Jamie Thompson, Andrius Masedunskas, Kantima Leelahavanichkul, Vyomesh Patel, Alfredo Molinolo, J. Silvio Gutkind, and Roberto Weigert

1389
MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
San-Jian Yu, Jing-Ying Hu, Xue-Ying Kuang, Jian-Min Lao, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Hou-Yan Song, and Zhi-Ming Shao

1400
HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
Jianghua Zheng, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xiumin Wang, Yu Zhu, Gang Xiao, Guangsun Cheng, Meizhong Zhao, Jian Zhang, and Jianhua Wang

1411
Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer
CANCER THERAPY: PRECLINICAL

1422 Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, and Kazuma Ohayahski
See commentary, p. 1309

1433 Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
Ying Zhang, Kaitlyn E. Farenholtz, Yanzhi Yang, Fadila Guessous, Charles G. diPierro, Valerie S. Calvert, Jianghong Deng, David Schiff, Wenjun Xin, Jae K. Lee, Benjamin Purrow, James Christensen, Emanuel Petricoin, and Roger Abounader

1445 Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
Lorenz Bastian, Jana Hof, Madlen Pfau, Iduna Fichtner, Cornelia Eckert, Günther Henze, Javier Prada, Arend von Stackelberg, Karl Seeger, and Shabnam Shalapour

1458 Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Eric I. Zimmerman, Shuiliying Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. Orwrick, Lie Li, Alex Sparreboom, and Sharyn D. Baker

1467 Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
Teun Guichelaar, Maarten E. Emmelot, Henk Rozemuller, Bianka Martini, Richard W.J. Groen, Gert Storm, Henk M. Lokhorst, Anton C. Martens, and Tuna Mutis

IMAGING, DIAGNOSIS, PROGNOSIS

1487 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors
Anish Thomas, Esther Mena, Karen Kurdziel, David Venzon, Sean Khozim, Arlene W. Berman, Peter Choyke, Eva Szabo, Arun Rajan, and Giuseppe Giaccone

1494 Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma

1503 Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Beom Kyung Kim, Seung Up Kim, Myeong-Jin Kim, Kyung Ah Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, and Chae Yoon Chon
See commentary, p. 1312

CANCER THERAPY: CLINICAL

1512 Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Kent A. Griffith, Rachel M. Layman, Ian Krop, Lacey A. Paskett, Helen Wong, Lacey E. Dobrolecki, Michael T. Lewis, Amber M. Froehlich, Jaya Paranilam, Daniel F. Hayes, Mark S. Wicha, and Jenny C. Chang

1525 Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
| 1534 | Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization | 1587 | Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Irinotecan or Paclitaxel in Early-Stage Breast Cancer |
| 1547 | Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer | 1603 | CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC |
| 1557 | Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study | 1612 | A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer |
| 1567 | Phase I Study of GRN1005 in Recurrent Malignant Glioma | 1620 | Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy |

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

| 1577 | A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients | 1596 | Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients |
| 1596 | PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE | 1603 | CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC |
| 1577 | A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients | 1603 | CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC |
| 1603 | A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer | 1620 | Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy |

The Journal of Clinical and Translational Research v www.aacrjournals.org Downloaded from clincancerres.aacrjournals.org on April 20, 2017. © 2013 American Association for Cancer Research.
ABOUT THE COVER

The microphotograph shows the induction of apoptosis after combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in a xenograft mouse model of acute lymphoblastic leukemia (ALL). Human B-cell precursor ALL cells were injected subcutaneously into nonobese diabetic/severe combined immunodeficient mice. Tumor sections after treatments were stained with mAbs against human CD10 (red) indicating leukemia cells, cleaved caspase-3 (green) indicating apoptotic cells, and 4',6-diamidino-2-phenylindole (nuclei, blue). For details, please see the article by Bastian and colleagues on page 1445 of this issue.